• AI
  • Molecular Imaging
  • CT
  • X-Ray
  • Ultrasound
  • MRI
  • Facility Management
  • Mammography

New SPECT System Addresses Need for Accessible Healthcare Technology at Low Dose

Article

(Press Release) GE Healthcare is offering a new fully upgradeable SPECT technology that allows patient dose as low as 50 percent of those of standard nuclear medicine scanning protocols†, or the potential for patients to spend significantly less time on the table during exams†, all without compromising image quality.

GE Healthcare is offering a new fully upgradeable SPECT technology that allows patient dose as low as 50 percent of those of standard nuclear medicine scanning protocols†, or the potential for patients to spend significantly less time on the table during exams†, all without compromising image quality.

The new GE Healthcare Discovery NM630 is engineered to help accommodate more patients than previous generation GE nuclear medicine systems. With its large 28” (70cm) wide bore and table capable of handling patients up to 500lbs. (227 kilograms), the Discovery NM630 provides access to a wide variety of patient sizes.

The more precise the information healthcare providers can get about a patient’s condition, the more effectively that patient can be treated. A step forward in detector design, the Elite NXT detector enables exceptional image quality. Elite NXT detectors are designed to offer outstanding SPECT resolution and exceptional contrast for superb image quality, all to help clinicians diagnose patients earlier and more accurately.  Ultra-thin design and auto-body contouring minimize the distance between the patient and the detectors for excellent resolution while SPECT-optimized collimators and the exceptionally high count rate enable extremely precise event detection.

Innovative and advanced Evolution* technology changes the relationship between time, dosage and image quality by allowing clinicians to reduce time or injected patient dose by up to 50 percent in most scanning procedures while maintaining excellent image quality†.

Discovery NM 630 ignites streamlined workflow by offering half-time imaging† and fast and flexible robotic gantry motions to enable a whole body and SPECT bone protocol in 15 minutes.

“Your reason for being is the health of countless patients who come to you for care,” said Nathan Hermony, general manager GE Healthcare Nuclear Medicine business. “This is why GE Healthcare strives to make advanced imaging technology more accessible. It is why GE Healthcare products are designed to help clinicians deliver not only an accurate diagnosis, but do it with comfort and peace-of-mind for your patients. It is why GE Healthcare created the Discovery NM630.”

The Discovery NM630 can be upgraded on location to a Discovery NM/CT 670 by adding CT capabilities that can expand services to true hybrid imaging, helping to protect clinicians’ investment through the ability to expand diagnostic horizons as the practice requires and the care mission demands.

The advanced Xeleris* workstation--which integrates new and existing nuclear medicine equipment, including legacy GE and non-GE devices-is designed to provide consistent results and enhanced workflow. Xeleris can keep clinicians connected to images and applications from PACS and PCs within their institution and remotely.

†Shorter acquisition times and dose reduction capabilities are possible with the Discovery NM 630 system only when used in combination with the relevant features offered on the Xeleris 3 processing and review workstation.

*Trademark of General Electric Company

 

Recent Videos
Computed Tomography Study Shows Emergence of Silicosis in Engineered Stone Countertop Workers
Can an Emerging AI Software for DBT Help Reduce Disparities in Breast Cancer Screening?
Skeletal Muscle Loss and Dementia: What Emerging MRI Research Reveals
Magnetoencephalopathy Study Suggests Link Between Concussions and Slower Aperiodic Activity in Adolescent Football Players
Radiology Study Finds Increasing Rates of Non-Physician Practitioner Image Interpretation in Office Settings
Assessing a Landmark Change in CMS Reimbursement for Diagnostic Radiopharmaceuticals
Addressing the Early Impact of National Breast Density Notification for Mammography Reports
2 KOLs are featured in this series.
2 KOLs are featured in this series.
Can 18F-Floutufolastat Bolster Detection of PCa Recurrence in Patients with Low PSA Levels After Radical Prostatectomy?
Related Content
© 2024 MJH Life Sciences

All rights reserved.